

North Central Cancer Treatment Group

N027D: A Phase I Study of CCI-779 and Temozolomide in Combination with Radiation Therapy in Glioblastoma Multiforme

Update 2 – December 17, 2010

Summary

Administrative changes.

Replacement pages are included. Please incorporate into the protocol and keep this update with your protocol.

Title page: Now reflects Update 2 and revised NCI version date.

Protocol Resources

Page 2: **Carla R. Hilton** replaces ~~Debra K. (Butch) Kvittum~~ as the NCCTG *Research Base* Quality Control Specialist.

The Research Base Data Management Specialist contact information has been removed (Vicki A. Bryhn). Please contact the NCCTG Research Base Quality Assurance Specialist (QAS) for technical questions regarding electronic form entry.